Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.78 USD | -3.58% | -8.29% | -41.00% |
04-25 | Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained | MT |
04-25 | Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.00% | 797M | |
+9.82% | 106B | |
+0.95% | 104B | |
+6.72% | 23.25B | |
-13.75% | 22.5B | |
-6.64% | 18.7B | |
-37.26% | 17.95B | |
-10.87% | 16.99B | |
+8.24% | 14.26B | |
+38.99% | 12.76B |
- Stock Market
- Equities
- SAGE Stock
- News Sage Therapeutics, Inc.
- Sage Therapeutics : Oppenheimer Adjusts Sage Therapeutics PT to $100 From $102, Maintains Outperform Rating